Acute Respiratory Distress Syndrome Clinical Trial
Official title:
Flow Versus Pressure Controlled Ventilation in Patients With Moderate to Severe Acute Respiratory Distress Syndrome
The goal of this clinical trial is to compare flow-controlled ventilation (FCV) and pressure-controlled ventilation (PCV) in patients with moderate to severe acute respiratory distress syndrome on the intensive care unit. The main questions it aims to answer are: - Is the mechanical power during flow-controlled ventilation lower than during pressure-controlled ventilation - To gain more understanding about other physiological effects and potential benefits of flow-controlled ventilation in comparison to pressure-controlled ventilation (o.a. the end-expiratory lung volume and homogeneity of ventilation). Participants will be randomized between two ventilation mode sequences, being 90 minutes of FCV followed by 90 minutes of PCV or vice versa.
Status | Recruiting |
Enrollment | 28 |
Est. completion date | May 2026 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older - Provided written informed consent - Undergoing controlled mechanical ventilation via an endotracheal tube - Meeting all criteria of the Berlin definition of ARDS - Hypoxic respiratory failure within 1 week of a known clinical insult or new or worsening respiratory symptoms - Bilateral opacities on X-ray or CT-scan not fully explained by effusions, lobar/lung collapse (atelectasis), or nodules - Respiratory failure not fully explained by cardiac failure or fluid overload. - Oxygenation: moderate ARDS P/F ratio between 101-200 mmHg, severe ARDS PF ratio = 100mmHg, both with PEEP = 5 cmH2O. - Intubated =72 hours Exclusion Criteria: - Severe sputum stasis or production requiring frequent bronchial suctioning (more than 5 times per nurse shift) - Untreated pneumothorax (i.e., no pleural drainage) - Hemodynamic instability defined as a mean arterial pressure below 60mmHg not responding to fluids and/or vasopressors or a noradrenalin dose >0.5mcrg/kg/min - High (>15 mmHg) or instable (an increase in sedation or osmotherapy is required) intracranial pressure - An inner tube diameter of 6mm or less - Intubated > 72 hours - Anticipating withdrawal of life support and/or shift to palliation as the goal of care - Inability to perform adequate electrical impedance tomography (EIT) measurements with, e.g.: - Have a thorax circumference inappropriate for EIT-belt - Thoracic wounds, bandages or deformities preventing adequate fit of EIT-belt - Recent (<7 days) pulmonary surgery including pneumonectomy, lobectomy or lung transplantation - ICD device present (potential interference with proper functioning of the EIT device and ICD device) - Excessive subcutaneous emphysema - Contra-indications for nasogastric tube or inability to perform adequate transpulmonary pressure measurements with, e.g.: - Recent esophageal surgery - Prior esophagectomy - Known presence of esophageal varices - Severe bleeding disorders |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maasstad Hospital | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center | Maasstad Hospital |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mechanical power | Difference in mechanical power in J/min after 90 minutes of flow-controlled ventilation and 90 minutes of pressure-controlled ventilation | 90 minutes | |
Secondary | End-expiratory lung volume | Difference in end-expiratory lung volume in milliliters after 30 minutes of flow-controlled ventilation and 30 minutes of pressure-controlled ventilation | 30 minutes | |
Secondary | Dissipated energy | Difference in dissipated energy in J/L after 90 minutes of flow-controlled ventilation and 90 minutes of pressure-controlled ventilation | 90 minutes | |
Secondary | Airway pressures | Difference in airway pressures in cmH2O (PEEP, PEEPtotal, Ppeak, Pplateau, Pdrive) between FCV and PCV | 30 and 90 minutes | |
Secondary | Transpulmonary pressures | Difference in transpulmonary pressures in cmH2O (end-inspiratory transpulmonary pressure, end-expiratory transpulmonary pressure and transpulmonary drivepressure) between FCV and PCV | 30 and 90 minutes | |
Secondary | Minute volume | Difference in minute volume in L/min between FCV and PCV | 30 and 90 minutes | |
Secondary | Ventilatory ratio | Difference in ventilatory ratio between FCV and PCV | 30 and 90 minutes | |
Secondary | Electrical Impedance Tomography (EIT) | Difference in EIT measurements between FCV and PCV (o.a. homogeneity of ventilation) | 30 and 90 minutes | |
Secondary | P/F ratio | Difference in P/F ratio between FCV and PCV | 30 and 90 minutes | |
Secondary | Mean arterial pressure | Difference in mean arterial pressure (mmHg) between FCV and PCV | 30 and 90 minutes | |
Secondary | Pulserate | Difference in pulserate (x/min) between FCV and PCV | 30 and 90 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |